Deciphera Pharmaceuticals, Inc. (DCPH)

Trade DCPH now with
2/13/2020 10:40:35 PM Deciphera Pharma Prices Public Offering Of 3.18 Mln Shares At $55/Shr
12/16/2019 7:11:33 AM Deciphera Pharma Announces Submission Of NDA To FDA For Ripretinib
10/2/2019 7:12:42 AM Deciphera Appoints Matthew Sherman As EVP And Chief Medical Officer
8/14/2019 11:46:46 PM Deciphera Pharma Prices Underwritten Public Offering Of 10.81 Mln Shares At $37.00/shr
8/13/2019 7:07:47 AM Deciphera Pharma Reports Positive Updated Phase 1 Data For Ripretinib In Gastrointestinal Stromal Tumors
7/8/2019 4:14:05 PM Deciphera Pharmaceuticals Appoints Susan Kelley To Its Board Of Directors
6/11/2019 7:09:14 AM Deciphera Pharma And Zai Lab Announce Exclusive License Agreement For Ripretinib In Greater China
6/10/2019 7:07:08 AM Deciphera Pharma Adds New Candidate To Its Pipeline, DCC-311 To Treat Mutant RAS Cancers
1/3/2019 7:33:46 AM Deciphera Initiates Phase 1b/2 Trial Of Rebastinib In Combination With Carboplatin In Advanced/Metastatic Solid Tumors
1/2/2019 7:35:00 AM Deciphera Pharma Announces Positive Top-Line Clinical Data For Ongoing Phase 1 Clinical Study With DCC-3014
12/20/2018 7:05:58 AM Deciphera Pharmaceuticals Initiates Pivotal Phase 3 Clinical Study Of Ripretinib
11/8/2018 7:14:17 AM Deciphera Pharmaceuticals Q3 Net Loss Widens To $24.4 Mln From $12.0 Mln Last Year
10/23/2018 7:11:42 AM Deciphera Begins Phase 1b/2 Study Of Rebastinib In Combination With Paclitaxe
10/19/2018 8:07:48 AM Deciphera Presents Updated Preliminary Results From Ongoing Phase 1 Clinical Study Of DCC-2618